

Letter of the Management Board

Dear Shareholders,

We are happy to provide you with information on the results of Medicalgorithmics S.A. for the year 2014. According to our last year's forecasts, 2014 was another successful year for us. Our technologies keep conquering the world with unflagging energy and the level of our profitability is still more than satisfying.

The upcoming years are going to mark a period of fast geographical expansion and development of new products. Each stage of our company's development is characterized by a different logic of problems. At this point we would like to thank our employees who face these problems every day and are committed to resolving them. We would also like to thank our customers, counterparties and partners for their cooperation to date.

Currently we perceive the Company's financial condition as very good and see no signs that it is going to change in the near future. Sales revenues amounted to PLN 29.7 million – the largest number in the Company's history, and the net result stood at the record-breaking level of PLN 14.5 million. Additionally, we managed to reach the impressive net profit margin level of 48.9%. The American market remains the primary driving force behind our growth. However, this is not the only market on which we operate. The international sales department set up in 2013 ensured our presence in countries such as Spain, Australia, India and Mexico. We are currently working hard to enter subsequent new markets: Brazil, Japan and the Middle East.

We can also proudly say that we were able to keep the promise to transfer the Company's shares to the main floor of the Warsaw Stock Exchange smoothly, so that the shares of Medicalgorithmics S.A. debuted as early as on February 3rd 2014.

In October 2014 we successfully completed a shift of production to a new, larger facility. The expansion of our production is directly related to the vast commercial success of the third generation of PocketECG and the constantly growing demand for our product.

The use of achievements of the latest technology for improving the state of health and efficient management of both doctors' and patients' time

is currently one of the fastest growing trends in developed countries. Our latest product supports this trend. That's why we have been increasingly affected by the positive change in approach of decision makers, insurance companies and doctors to the modern diagnostic equipment used for tele-cardiology. The changing approach results in an increase of our current markets, also in the USA, where large insurance companies have started to refund long-term cardiological examinations. In less favoured regions, these markets are still emerging, but they are growing dynamically on account of changes in legislation being introduced and new refund codes related to multi-day monitoring.

Our employees keep improving the product from the engineering and programming perspective, developing its functionalities and creating new ones, which opens new potential markets for us.

As you can see, we can declare the previous year successful to our Company. We look to the future with optimism as implementation of newly signed agreements and expansion to subsequent markets is still ahead of us. We hope to boast record-breaking financial results and a broad range of customers and markets this time next year. We hope you will stay with us and participate in this shared success.

On behalf of the Company's

Management Board:

Warsaw, March 18 2015



Marek Dziubiński

President of the



Piotr Żółkiewicz

Vice President of the
in charge of financial and



Tomasz Mularczyk

Vice President of the